clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Hahn DL et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. 1998 Ann. Allergy Asthma Immunol. pmid:9475566
Price J and Hamilton W Pragmatic eradication of H. pylori. 1997 Br J Gen Pract pmid:9474836
Tzivras M et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. 1997 Eur J Gastroenterol Hepatol pmid:9471024
Preston SL et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. 1998 AIDS pmid:9468380
Torresani C et al. Clarithromycin versus doxycycline in the treatment of rosacea. 1997 Int. J. Dermatol. pmid:9466207
Hoffner SE et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. 1997 J. Antimicrob. Chemother. pmid:9462443
Loo VG et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. 1997 J. Antimicrob. Chemother. pmid:9462442
Misiewicz JJ et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. 1997 Gut pmid:9462204
Briant C et al. Pericarditis as a manifestation of Lyme disease. 1997 J Emerg Nurs pmid:9460386
Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. 1998 JAMA pmid:9459473
Thornsberry C et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. 1997 Diagn. Microbiol. Infect. Dis. pmid:9458982
Goujard C et al. Clarithromycin-resistant Mycobacterium avium strain in a clarithromycin-naive AIDS patient. 1998 Clin. Infect. Dis. pmid:9455532
Sax L Bacterial pharyngitis in children. 1998 J Fam Pract pmid:9451356
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Forné M et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. 1998 Am. J. Gastroenterol. pmid:9448170
Fennerty MB Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. 1998 Am. J. Gastroenterol. pmid:9448162
Genné D et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447898
Prattichizzo FA et al. [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. 1997 Minerva Cardioangiol pmid:9446067
Mikamo H et al. Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. 1998 Jan-Feb Chemotherapy pmid:9444409
Gotoh A et al. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 Microbiol. Immunol. pmid:9444328
Suzuki K et al. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. 1997 Int. J. Tuberc. Lung Dis. pmid:9441102
Burman WJ et al. A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. 1997 Int. J. Tuberc. Lung Dis. pmid:9441082
Yatsunami J et al. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. 1997 Res Exp Med (Berl) pmid:9440137
Dixon JS et al. Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori. 1997 J. Physiol. Pharmacol. pmid:9440055
Bazzoli F and Pozzato P Therapy of H. pylori infection. 1997 J. Physiol. Pharmacol. pmid:9440054
Akiyama H et al. Biofilm formation of Staphylococcus aureus strains isolated from impetigo and furuncle: role of fibrinogen and fibrin. 1997 J. Dermatol. Sci. pmid:9438901
Lerang F et al. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. 1997 Scand. J. Gastroenterol. pmid:9438318
Reisner BS et al. Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin. 1997 Int. J. Tuberc. Lung Dis. pmid:9432376
Pounder RE et al. Ranitidine bismuth citrate with clarithromycin for the eradication of Helicobacter pylori and for ulcer healing. 1997 Helicobacter pmid:9432341
Pieramico O et al. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. 1997 Helicobacter pmid:9432335
Takimoto T et al. The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. 1997 Helicobacter pmid:9432334
Bardhan KD et al. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. 1997 Helicobacter pmid:9432318
McLaren A et al. The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. 1997 Helicobacter pmid:9432317
Stone GG et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. 1996 Helicobacter pmid:9432314
Feldman C et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. 1997 Inflammation pmid:9429912
Butt AA Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. 1998 Am. J. Med. Sci. pmid:9427575
Midolo PD et al. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. 1997 Pathology pmid:9423225
Matsunaga K et al. [Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy]. 1997 Gan To Kagaku Ryoho pmid:9422074
O'Connor HJ et al. One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? 1997 Helicobacter pmid:9421124
Hultén K et al. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. 1997 Helicobacter pmid:9421122
Tompkins DS et al. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. 1997 Helicobacter pmid:9421121
Pipkin GA et al. Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review. 1997 Helicobacter pmid:9421117
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Shafran SD et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. 1998 J. Infect. Dis. pmid:9419201
Greco S et al. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. 1997 Ann Pharmacother pmid:9416400
Barry AL et al. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9405952
Sander P et al. The role of ribosomal RNAs in macrolide resistance. 1997 Mol. Microbiol. pmid:9402018
Martin SJ et al. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. 1997 Diagn. Microbiol. Infect. Dis. pmid:9401809
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
van der Hulst RW et al. Treatment of Helicobacter pylori infection: a review of the world literature. 1996 Helicobacter pmid:9398908
Lind T et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. 1996 Helicobacter pmid:9398894
O'Morain C et al. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. 1996 Helicobacter pmid:9398893
Mégraud F and Malfertheiner P Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995. 1996 Helicobacter pmid:9398889
Moayyedi P et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. 1996 Helicobacter pmid:9398880
Jaup BK Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin. 1996 Helicobacter pmid:9398878
Schwartz H et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. 1996 Helicobacter pmid:9398876
Harford W et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. 1996 Helicobacter pmid:9398875
Riff DS et al. Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report. 1996 Helicobacter pmid:9398874
Ando H et al. [Changes in serum anti-Helicobacter pylori IgG antibody, pepsinogen I, and pepsinogen II after eradication therapy of Helicobacter pylori]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9396326
Suzuki Y et al. [Antimicrobial activities of clarithromycin against recent obtained clinical isolates]. 1997 Jpn J Antibiot pmid:9394238
Anzueto A et al. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. 1997 Sep-Oct Clin Ther pmid:9385486
Stephenson GA et al. Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. 1997 J Pharm Sci pmid:9383733
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Tartaglione T Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. 1997 Jul-Aug Clin Ther pmid:9377608
Hultén K et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. 1997 Antimicrob. Agents Chemother. pmid:9371366
Buckley MJ et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. 1997 Dig. Dis. Sci. pmid:9365144
Ramirez Mayans JA et al. [Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin]. 1996 Acta Gastroenterol. Latinoam. pmid:9363265
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Zuberi BF et al. Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer. 1997 J Pak Med Assoc pmid:9361485
Dubé MP et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. 1997 J. Infect. Dis. pmid:9359722
Grosset J and Ji B Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. 1997 Drugs pmid:9358197
Jablonowski H et al. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients. 1997 Drugs pmid:9358196
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Harris A H. pylori eradication by LAC. 1997 Aliment. Pharmacol. Ther. pmid:9354216
Wurzer H et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. 1997 Aliment. Pharmacol. Ther. pmid:9354205
Breuer T et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. 1997 Aliment. Pharmacol. Ther. pmid:9354204
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Laine L et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9354200
Lévy M et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. 1997 Gastrointest. Endosc. pmid:9351036
Pendland SL et al. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. 1997 J. Clin. Microbiol. pmid:9350781
Yasui N et al. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. 1997 Int Clin Psychopharmacol pmid:9347384
Rodrigues AD and Wong SL Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. 1997 Adv. Pharmacol. pmid:9342173
Szántó D et al. [Could Helicobacter pylori cause reactive arthro-osteitis?]. 1997 Orv Hetil pmid:9340585
Jingu K et al. [A case of fluminant Mycoplasma pneumonia and bronchiolitis managed by artificial respiration]. 1997 Nippon Naika Gakkai Zasshi pmid:9340346
Brancato R et al. Mycobacterium chelonae keratitis after excimer laser photorefractive keratectomy. 1997 Arch. Ophthalmol. pmid:9338681
Mitsuyama T et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. 1997 Int. Arch. Allergy Immunol. pmid:9338603
Kundu S et al. Clarithromycin-induced ventricular tachycardia. 1997 Ann Emerg Med pmid:9326871
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
Chey WD et al. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. 1997 Am. J. Gastroenterol. pmid:9317068
Picardeau M et al. Use of different molecular typing techniques for bacteriological follow-up in a clinical trial with AIDS patients with Mycobacterium avium bacteremia. 1997 J. Clin. Microbiol. pmid:9316897
Wright DH Regression of mucosa-associated lymphoid-tissue lymphoma after eradication of Helicobacter pylori. 1997 Lancet pmid:9314895
May T et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. 1997 Clin. Infect. Dis. pmid:9314450
Finkenbine R and Gill HS Case of mania due to prednisone-clarithromycin interaction. 1997 Can J Psychiatry pmid:9307841
Sánchez-Nuñez ML et al. Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia. 1997 Nephrol. Dial. Transplant. pmid:9306384
Williams MP et al. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. 1997 Aliment. Pharmacol. Ther. pmid:9305479
Savarino V et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 1997 Aliment. Pharmacol. Ther. pmid:9305478
Mor N and Esfandiari A Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. 1997 Antimicrob. Agents Chemother. pmid:9303411